Controlled and sustained delivery of drugs for ophthalmic diseases continues to remain a
major challenge in the field of pharmaceutical drug delivery. To overcome the problems of …

Delivering therapeutics to the eye is challenging on multiple levels: rapid clearance of
eyedrops from the ocular surface requires frequent instillation, which is difficult for patients; …

Ocular diseases can deteriorate vision to the point of blindness and thus can have a major
impact on the daily life of an individual. Conventional therapies are unable to provide …

Commercially available ocular drug delivery systems are effective but less efficacious to
manage diseases/disorders of the anterior segment of the eye. Recent advances in …

Over the past decade, there has been a rise in the number of clinical cases of moderate to
severe anterior segment ocular diseases. Conventional topical ophthalmic formulations …

Numerous novel nano-based ocular drug delivery systems have been developed to
overcome the limitations of conventional drug delivery systems, which have demonstrated …

The topical route is the most frequent and preferred way to deliver drugs to the eye.
Unfortunately, the very low ocular drug bioavailability (less than 5%) associated with this …

Ocular drug delivery has seen several advances in the past few decades, with respect to
new drugs, improved formulations, targeted delivery, as well as exploration of new routes of …

Despite intense research efforts; effective delivery of drugs to the eye remains an enormous
challenge. The eye is a unique organ with complex structure and functions. It is protected by …

In the past three decades, the application of nanotechnology in ophthalmology has gained
considerable progress for the treatment of ocular diseases including anterior and posterior …